Fiorenza De Rose

Dr. Fiorenza De Rose

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
TCTiziana Comito
Tiziana Comito
LCL. Cozzi
L. Cozzi
ECElena Clerici
Elena Clerici
CFCiro Franzese
Ciro Franzese
ATA. Tozzi
A. Tozzi
MSMarta Scorsetti
Marta Scorsetti
To assess the efficacy of stereotactic body radiotherapy in patients with unresectable locally advanced pancreatic cancer. All patients received a prescription dose of 45 Gy in 6 fractions. Primary end point was freedom from local progression. Secondary end points were overall survival, progression-free survival, and toxicity. Actuarial survival analysis and univariate or multivariate analysis were investigated. Forty-five patients were enrolled in a phase 2 trial. Median follow-up was 13.5 months. Freedom from local progression was 90% at 2 years. On univariate (P < .03) and multivariate analyses (P < .001), lesion size was statistically significant for freedom from local progression. Median progression-free survival and overall survival were 8 and 13 months, respectively. On multivariate analysis, tumor size (P < .001) and freedom from local progression (P < .002) were significantly correlated with overall survival. Thirty-two (71%) patients with locally advanced pancreatic cancer received chemotherapy before stereotactic body radiotherapy. Median overall survival from diagnosis was 19 months. Multivariate analysis showed that freedom from local progression (P < .035), tumor diameter (P < .002), and computed tomography before stereotactic body radiotherapy (P < .001) were significantly correlated with overall survival from diagnosis. Stereotactic body radiotherapy is a safe and effective treatment for patients with locally advanced pancreatic cancer with no G3 toxicity or greater and could be a promising therapeutic option in multimodality treatment regimen.

27 August 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TCTiziana Comito
Tiziana Comito
LCLuca Cozzi
Luca Cozzi
ECElena Clerici
Elena Clerici
MCMaria Concetta Campisi
Maria Concetta Campisi
RLRocco Luca Emanuele Liardo
Rocco Luca Emanuele Liardo
MSMarta Scorsetti
Marta Scorsetti
To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer. 82 patients with 1–3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity. Median follow-up was 24 months (range 3–47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to 85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity. SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.

1 March 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Pierina NavarriaPierina Navarria
Pierina Navarria
AAAnna Maria Ascolese
Anna Maria Ascolese
LCLuca Cozzi
Luca Cozzi
STStefano Tomatis
Stefano Tomatis
GDGiuseppe Roberto D’aGostino
Giuseppe Roberto D’aGostino
MSMarta Scorsetti
Marta Scorsetti

2 April 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Pierina NavarriaPierina Navarria
Pierina Navarria
AAAnna Maria Ascolese
Anna Maria Ascolese
STStefano Tomatis
Stefano Tomatis
LCLuca Cozzi
Luca Cozzi
FRFiorenza De Rose
Fiorenza De Rose
MSMarta Scorsetti
Marta Scorsetti
Data in the literature suggest the existence of oligometastatic disease, a state in which metastases are limited in number and site. Different kinds of local therapies have been used for the treatment of limited metastases and in the recent years reports on the use of Stereotactic Ablative radiotherapy (SABR) are emerging and the early results on local control are promising. From October 2010 to February 2012, 76 consecutive patients for 118 lung lesions were treated. SABR was performed in case of controlled primary tumor, long-term of progression disease, exclusion of surgery, and number of metastatic sites ≤ 5. Different kinds of primary tumors were treated, the most common were lung and colon-rectal cancer. The total dose prescribed varied according to tumor site and maximum diameter. Dose prescription was 48 Gy in 4 fractions for peripheral lesions, 60 Gy in 8 fractions for central lesions and 60 Gy in 3 fractions for peripheral lesions with diameter ≤ 2 cm. Dosimetric planning objectives were met for the cohort of patients with in particular V98% = 98.1 ± 3.4% for the CTV and mean lung dose of 3.7 ± 3.8 Gy. Radiological response was obtained in the vast majority of patients. The local control at 1, 2 and 3 years was 95%, 89% and 89% respectively. No major pulmonary toxicity, chest pain or rib fracture occurred. The median follow up was 20 months (range 6–45 months). Overall Survival (OS) at 1, 2 and 3 years was 84.1%, 73% and 73% respectively. SABR is feasible with limited morbidity and promising results in terms of local contro, survival and toxicity.

3 January 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
AFAntonella Fogliata
Antonella Fogliata
JSJan Seppälä
Jan Seppälä
GRGiacomo Reggiori
Giacomo Reggiori
FLFrancesca Lobefalo
Francesca Lobefalo
VPValentina Palumbo
Valentina Palumbo
LCLuca Cozzi
Luca Cozzi
Objective: Breast planning with volumetric modulated arc therapy (VMAT) has been explored, especially for left-sided breast treatments, with the primary intent of lowering the heart dose and improving target dose homogeneity. As a trade-off, larger healthy tissue volumes would receive low dose levels, with the potential risk of increasing late toxicities and secondary cancer induction, although no clinical data are available today to confirm the risk level. The scope of this work is to explore the dosimetric trade-offs using two different VMAT plans. Methods: Two planning strategies for dual-partial-arc VMAT, RA_avoid and RA_full, with and without avoidance sectors, were explored in a cohort of 20 patients, for whole left breast irradiation for 40.05 Gy to the mean target dose in 15 fractions. Common dose objectives included a stringent dose homogeneity, mean dose to the heart <5 Gy, ipsilateral lung (I lung) <8 Gy, contralateral lung (C lung) <2 Gy and contralateral breast (C breast) <3 Gy. Results: RA_full showed a better dose conformity, lower high-dose spillage in the healthy tissue and lower skin dose. RA_avoid presented a reduction of the mean doses for all critical structures: 51% to the heart, 12% to the I lung, 81% to the C lung and 73% to the C breast. All differences were significant with p < 0.0001. Conclusion: The adaptation of VMAT options to planning objectives reduced significantly the healthy tissue dose levels at the price of some high-dose spillage. Evaluation of the trade-offs for application to the different critical structures should drive in improving the usage of the VMAT technique for breast cancer treatment. Advances in knowledge: Different planning strategies in the same VMAT technique could give significant variations in dose distributions. The choice of the trade-offs would affect the possible future late toxicity and secondary cancer induction risk.

2 June 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Pierina NavarriaPierina Navarria
Pierina Navarria
FPFederico Pessina
Federico Pessina
LCLuca Cozzi
Luca Cozzi
AAAnna Maria Ascolese
Anna Maria Ascolese
FRFiorenza De Rose
Fiorenza De Rose
MSMarta Scorsetti
Marta Scorsetti
Hypo-fractionated stereotactic radiotherapy (HSRT) is emerging as a valid treatment option for patients with single, large brain metastases (BMs). We analyzed a set of our patients treated with HSRT. The aim of this study was to evaluate local control (LC), brain distant progression (BDP), toxicity and overall survival (OS). From July 2011 to May 2015, 102 patients underwent HSRT consisting of 27Gy/3fractions for lesions 2.1–3 cm and 32Gy/4 fractions for lesions 3.1–5 cm. Local progression was defined as increase of the enhancing abnormality on MRI, and distant progression as new brain metastases outside the irradiated volume. Toxicity in terms of radio-necrosis was assessed using contrast enhanced T1MRI, T2 weighted-MRI and perfusion- MRI. The median maximum diameter of BM was 2.9 cm (range 2.1–5 cm), the median gross target volume (GTV) was 16.3 cm3 and the median planning target volume (PTV) was 33.7 cm3 The median,1,2-year local control rate was 30 months, 96, 96 %; the median, 1–2-year rate of BDP was 24 months, 12, 24 %; the median,1,2-year OS was 14 months, 69, 33 %. KPS and controlled extracranial disease were associated with significant survival benefit (p <0.01). Brain radio-necrosis occurred in six patients (5.8 %). In patients with single, large BMs unsuitable for surgical resection, HSRT is a safe and feasible treatment, with good brain local control and limited toxicity.